Thursday 10 September 2026

The Pharmaletter

VenatoRx Pharma

VenatoRx Pharmaceuticals is a private, clinical-stage pharmaceutical company dedicated to the discovery and development of new medicines to treat drug-resistant infections.

Company Overview

Want to Update your Company's Profile?


Latest VenatoRx Pharma News

GSK unveils pivotal Phase III win for oral antibiotic tebipenem HBr
22 October 2025
The week in pharma: action, reaction and insight – week to August 15
17 August 2025
Basilea inks antibiotic deal with Venatorx
15 August 2025
FDA slaps CRL on cefepime-taniborbactam NDA
26 February 2024
More VenatoRx Pharma news >


Today's issue

US generic and biosimilar meds save $496B in just 1 year
Generics
US generic and biosimilar meds save $496B in just 1 year
10 September 2026
Biotechnology
NICE backs Darzalex-based quadruplet for newly-diagnosed myeloma, J&J's second blood cancer win in a week
10 September 2026
Biotechnology
Tyra Biosciences Phase II SURF302 results support LG IR NMIBC with dabogratinib
10 September 2026
Biotechnology
Evommune's EVO756 misses primary endpoint in atopic dermatitis Phase IIb
10 September 2026
Biotechnology
FDA accepts Roche’s Enspryng sBLA for MOGAD
10 September 2026
Biotechnology
Solstice Oncology launches with $225 million to advance neoadjuvant CTLA-4 antibody
10 September 2026
Biotechnology
Alchemab Therapeutics expands leadership team
10 September 2026




Copyright © The Pharma Letter 2026

 |  Headless Content Management with Blaze